2023
Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems
Garcia-Manero G, McCloskey J, Griffiths E, Zeidan A, Yee K, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Lee S, Chan W, Souza S, Sano Y, Keer H, Savona M. Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems. Blood 2023, 142: 4619. DOI: 10.1182/blood-2023-188258.Peer-Reviewed Original ResearchInternational Prognosis Scoring SystemLow-risk MDSHigh-risk MDSLeukemia-free survivalIPSS-R scoreOverall survivalMDS subjectsClinical outcomesPatient outcomesC-indexConcordance indexScoring systemMDS/CMMLMedian overall survivalDifferent risk stratification systemsHarrell's concordance indexMyelodysplastic syndrome patientsHigh-risk populationRisk stratification systemHigh-risk categoryHR categoriesCycle 2Different risk categoriesTreatment discontinuationClinical response
2022
Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)
Savona M, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg J, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Oganesian A, Chan W, Hao Y, Azab M, Garcia-Manero G. Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02). Blood 2022, 140: 2066-2069. DOI: 10.1182/blood-2022-163841.Peer-Reviewed Original ResearchMDS subjects